June 11, 2021

 

Boehringer Ingelheim to prioritise R&D using AI

 


Boehringer Ingelheim announced earlier this week the beginning of a long-term partnership with Lifebit Biotech to utilise deep learning, natural language processing and artificial intelligence (AI) for the detection and early-reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources. Utilising the Lifebit REAL platform, insights into the latest infectious disease outbreaks allow R&D efforts to be prioritised accordingly.


Lifebit REAL automatically notifies users of relevant outbreaks, such as transboundary disease spread or the emergence of pathogens, such as COVID-19. The system is built around an active learning architecture: with more relevant data ingested, the accuracy of the system increases.


Dr. Eric Haaksma, head of Animal Health Global Innovation Boehringer Ingelheim, shared: "External innovation is becoming an increasingly important aspect of our R&D playbook. Therefore, we are strategically partnering with Lifebit to leverage AI to monitor and interpret scientific and other sources in real-time, enabling us to track data related to animal diseases. This, in turn, will accelerate the detection process as the vast amounts of scientific relevant information being produced at many levels cannot be feasibly collected and analysed manually."